MetaCap

Atea Pharmaceuticals (AVIR) vs Larimar Therapeutics (LRMR)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Atea Pharmaceuticals (AVIR) has outperformed Larimar Therapeutics (LRMR) over the past year, gaining 33.3% versus a loss of 11.8%. Over five years, AVIR leads with a -51.4% price change compared with -69.0% for LRMR. Larimar Therapeutics is the larger company by market cap ($328.6 million vs $318.0 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

AVIR+33.33%LRMR-11.80%
+115%+31%-52%
Nov 21, 20251 yearNov 20, 2026
AVIR-51.17%LRMR-69.37%
+30%-30%-91%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

AVIR versus LRMR key metrics
MetricAVIRLRMR
Share price$3.96$3.14
Market cap$318.00M$328.55M
1-day change+0.76%-2.48%
YTD return+10.92%-17.59%
1-year return+33.33%-11.80%
5-year return-51.35%-68.97%
EPS (TTM)$-1.95$-1.67
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-158.35M$-165.67M
52-week high$6.45$6.42
52-week low$2.96$1.92
Distance from 52-week high-38.60%-51.09%
Analyst consensusbuystrong_buy
Avg. price target upside+127.27%+352.23%
Average volume290.60K1.38M
Shares outstanding80.30M104.63M
Employees5571
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • AVIR has outperformed LRMR by 45.1 percentage points over the past year.

About Atea Pharmaceuticals

AVIR stock →

Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV).

Health Care · Biotechnology: Pharmaceutical Preparations · 55 employees

About Larimar Therapeutics

LRMR stock →

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal disease.

Health Care · Biotechnology: Pharmaceutical Preparations · 71 employees

AVIR vs LRMR FAQ

Which is bigger, Atea Pharmaceuticals or Larimar Therapeutics?

Larimar Therapeutics (LRMR) is larger, with a market capitalization of $328.55M compared with $318.00M for Atea Pharmaceuticals (AVIR).

Which stock has performed better over the past year, AVIR or LRMR?

AVIR returned +33.33% over the past 12 months, compared with -11.80% for LRMR (price return, excluding dividends). Past performance does not predict future results.

Are Atea Pharmaceuticals and Larimar Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons